Meeting
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
Authors
Joseph Vento
Vanderbilt University Medical Center, Nashville, TN
Joseph Vento, Scott Mattox Haake, Katy Beckermann, Brian I. Rini, Yu-Wei Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 532)
DOI
10.1200/OP.2023.19.11_suppl.532
Abstract #
532
Poster Bd #
L7
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2019 Genitourinary Cancers Symposium
Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
First Author: Anita Gul
Poster
2017 Genitourinary Cancers Symposium
Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
First Author: Steven Yip
Poster
2021 ASCO Annual Meeting
Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
First Author: Bradley Alexander McGregor